Skip to main content
SpringerLink
Log in

Measurement of patient compliance and the interpretation of randomized clinical trials

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The aim of this review is to demonstrate why the management of compliance, although not an explicit feature of the rules of Good Clinical Practice, is essential to the successful conduct of clinical trials and in correct interpretation of the results. Methods to measure compliance in randomized clinical trials are also described. The relevant literature was retrieved by a manual search of the Cumulated Index Medicus 1975–1989 and a MEDLINE computer search of publications in 1990 using the Medical Subject Headings “patient compliance” and “clinical trials”. All retrieved articles are discussed. Research into patient compliance has stagnated because of the lack of a “gold” standard of measurement. Nevertheless, management of compliance at the different stages of clinical trials is necessary; at trial design, compliance should be taken into account in sample size calculations; during the conduct of a trial, compliance should be monitored in order to safeguard the power of the study; and in interpretation of trial results, compliance data are helpful both in order to avoid erroneous conclusions and to enrich the value of the data. Compliance should be measured in all limbs of randomized trials, including the placebo limb, without breaking trial blinding. A classification of compliance behaviour into six types (complier, partial complier, overuser, erratic user, partial dropout and dropout) is proposed, based on the changes in the risk-benefit ratio produced by non-compliance. The use of deuterium oxide, low dose phenobarbitone (2 mg per day), digoxin (2,2 μg per day) and the new electronic monitoring devices are suitable methods for measurement in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fox W (1962) The self-administration of medicaments: a review of published work and a study of the problem. Bull Int Union Tub 32: 307–301

    Google Scholar 

  2. Steward RB, Cuff LE (1972) A review of medication errors and compliance in ambulant patients. Clin Pharmacol Ther 13: 463–468

    Google Scholar 

  3. Blackwell B (1973) Drug therapy: patient compliance. N Engl J Med 289: 249–252

    Google Scholar 

  4. Boyd JR, Covington TR, Stanaszek WF, Coussons TR (1974) Drug defaulting. Part i: determinants of compliance. Am J Hosp Pharm 31: 362–367

    Google Scholar 

  5. Boyd JR, Covington TR, Stanaszek WF, Coussons TR (1974) Drug defaulting. Part ii: analysis of non-compliance patterns. Am J Hosp Pharm 31: 485–491

    Google Scholar 

  6. Haynes RB, Taylor DW, Sackett DL (1979) Compliance in health care. Johns Hopkins University Press, Baltimore

    Google Scholar 

  7. Evans L, Spelman M (1983) The problem of non-compliance with drug therapy. Drugs 25: 63–76

    Google Scholar 

  8. Epstein LH (1984) The direct effects of compliance on health outcome. Health Psychol 3: 385–393

    Google Scholar 

  9. Becker MH (1985) Patient adherence to prescribed therapies. Med Care 23: 539–555

    Google Scholar 

  10. Lüscher TF, Vetter H, Siegenthaler W, Vetter W (1985) Compliance in hypertension: facts and concepts. J Hypertens 3 [Suppl 1]: 3–9

    Google Scholar 

  11. Cameron K, Gregor F (1987) Chronic illness and compliance. J Adv Nurs 12: 671–676

    Google Scholar 

  12. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD (1988) Patient non-compliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transpl Proc 20 [Suppl 3]: 63–69

    Google Scholar 

  13. Kopanoff DE, Snider DE, Johnson M (1988) Recurrent tuberculosis: why do patients develop disease again? A United States Public Health Service cooperative survey. Am J Public Health 78: 30–33

    Google Scholar 

  14. Levy M, Mermelstein L, Hemo D (1982) Medical admissions due to non-compliance with drug therapy. Int J Clin Pharmacol Ther Toxicol 12: 600–604

    Google Scholar 

  15. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR (1988) Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 36: 1092–1098

    Google Scholar 

  16. Ghali JK, Kadakia S, Cooper S, Ferlinz J (1988) Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med 148: 2013–2016

    Google Scholar 

  17. Davidsen F, Haghfelt T, Gram LF, Brøsen K (1988) Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department. Eur J Clin Pharmacol 34: 83–86

    Google Scholar 

  18. Bruer JT (1982) Methodological rigor and citation frequency in patient compliance literature. Am J Public Health 72: 1119–1123

    Google Scholar 

  19. Caron HS (1985) Compliance: the case for objective measurement. J Hypertens 3 [Suppl 1]: 11–17

    Google Scholar 

  20. Rudd P (1979) In search for the gold standard for compliance measurement [editorial]. Arch Intern Med 139: 627–628

    Google Scholar 

  21. Goldsmith CH (1979) The effect of compliance distributions on therapeutical trials. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. The Johns Hopkins University Press, Baltimore

    Google Scholar 

  22. Davis MS (1966) Variations in patient compliance with doctors orders: analysis of congruence between survey responders and results of empirical observations. J Med Educ 41: 1037–1048

    Google Scholar 

  23. Gillum RF, Barsky AJ (1974) Diagnosis and management of patient non-compliance. JAMA 228: 1563–1567

    Google Scholar 

  24. Ley P (1979) Memory for medical information. Br J Soc Clin Psychol 18: 245–255

    Google Scholar 

  25. Ley P (1982) Satisfaction, compliance and communication. Br J Clin Psychol 21: 241–254

    Google Scholar 

  26. Ley P (1985) Doctor-patient communication: some quantitative estimates of the role of cognitive factors in non-compliance. J Hypertens 3 (suppl 1): 51–55

    Google Scholar 

  27. Inui TS, Carter WB (1985) Problems and prospects for health services research on provider-patient research. Med Care 23: 521–538

    Google Scholar 

  28. Haynes B, Wang E, Da Mota Gomes M (1987) A critical review of interventions of improve compliance with prescribed medications. Patient Educ Counseling 10: 155–166

    Google Scholar 

  29. Cockburn J, Redman S, Sanson-Fisher RW (1988) Compliance aiding strategies: a guide for the busy practitioner. Australian Prescr 11: 52–54

    Google Scholar 

  30. Leventhal H (1985) The role of theory in the study of adherence to treatment and doctor-patient interactions. Med Care 23: 556–563

    Google Scholar 

  31. Joyce CRB (1962) Patient co-operation and the sensitivity of clinical trials. J Chronic Dis 15: 1025–1036

    Google Scholar 

  32. Blackwel B (1972) Commentary — The drug defaulter. Clin Pharm Ther 13: 841–848

    Google Scholar 

  33. Soutter BR, Kennedy HB (1974) Patient compliance assessment in drug trials: usage and methods. Aust NZ J Med 4: 360–364

    Google Scholar 

  34. Gore SM (1981) Assessing clinical trials — trial discipline. Br Med J 283: 211–213

    Google Scholar 

  35. Dunbar JM (1982) Assessment of medication compliance. In: Haynes RB, Mattson ME, Engebretsen TO jr. Patient compliance to prescrived antihypertensive medication regimes: a report to NHLBI. Hypertension 4: 415–423

    Google Scholar 

  36. Blaszkowski TP, Insull W (1984) Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 451–587

    Google Scholar 

  37. Norell SE (1984) Methods in assessing drug compliance. Acta Med Scand 683 [Suppl]: 35–40

    Google Scholar 

  38. Sleator EK (1985) Measurement of compliance. Psychopharmacol Bull 21: 1089–1093

    Google Scholar 

  39. Roth H (1987) Measurement of compliance. Pat Educ Counselling 10: 107–116

    Google Scholar 

  40. Pledger GW (1988) Compliance in clinical trials: impact on design, analysis and interpretation. Epilepsy Res 2 [Suppl 1]: 125–133

    Google Scholar 

  41. Rudd P, Byyny RL, Zachary V, Loverde ME, Mithchell WD, Titus C, Marshall G (1988) Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens 1: 309–312

    Google Scholar 

  42. Pullar T, Kumar S, Tindall H, Feely M (1989) Time to stop counting the tablets? Clin Pharmacol Ther 46: 163–168

    Google Scholar 

  43. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Quellette VL (1989) How often is medication taken as prescribed. A novel assessment technique [published erratum appears in JAMA (1989) 262: 1472]. JAMA 261: 3273–3277

    Google Scholar 

  44. Insull W (1984) Statement of the problem and pharmacological and clinical requirements for the ideal marker. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 459–465

    Google Scholar 

  45. Haynes RB, Dantes R (1987) Patient compliance and the conduct and interpretation of therapeutic trials. Controlled Clin Trials 8: 12–19

    Google Scholar 

  46. Cramer JA, Collins J, Mattson RH (1988) Can categorization of patient background problems be used to determine early termination in a clinical trial? Controlled Clin Trials 9: 47–63

    Google Scholar 

  47. Palta M, McHugh R (1980) Planning the size of a cohort study in the presence of both losses to follow-up and non-compliance. J Chron Dis 33: 501–512

    Google Scholar 

  48. Lakatos E (1986) Sample size determination in clinical trials with time-depent rates of losses and non-compliance. Controlled Clin Trials 7: 189–199

    Google Scholar 

  49. Ramsay JA (1982) Participants in non-compliance research: compliant or noncompliant? Med Care 20: 615–622

    Google Scholar 

  50. Feinstein AR (1979) “Compliance bias” and the interpretation of clinical trials. In: Haynes RB, Taylor DW, Sackett DL (eds). Compliance in health care. Baltimore: The Johns Hopkins University Press

    Google Scholar 

  51. Materson BJ, Oster JR, Michael UF et al (1978) Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther 24: 192–198

    Google Scholar 

  52. Nimran A, Jover B (1982) Maintainance of the antihypertensive efficacy of captopril despite consistant reduction in daily dosage. Br J Clin Pharmacol 14 (Suppl 2): 81S-85S

    Google Scholar 

  53. Urquhart J, Chevalley C (1988) Impact of unrecognized dosing errors on the cost and the effectiveness of pharmaceuticals. Drug Inform J 22: 363–378

    Google Scholar 

  54. The Lipid Research Clinic's Coronary Primary Prevention Trial results (1984) I. Reduction in the incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–374

    Google Scholar 

  55. Efron B, Feldman D (1989) Compliance as an explanatory variable in clinical trials. Technical report No 129, Stanford University, Stanford

    Google Scholar 

  56. Brittain E, Wittes J (1989) Factorial design in clinical trials: the effects of non-compliance and subadditivity. Stat Med 8: 161–171

    Google Scholar 

  57. Drug Information Association (1989) The impact of partial compliance in clinical trials. Philadelphia Workshop, Audiocassettes available from Audio Transcripts Ltd, Alexandria VA, USA

  58. Lasagna L (1989) Scientific and political components of regulatory decision making: the United States experience. In: Horrisberger B, Dinkel (eds). The perception and management of drug safety risks. New York: Springer-Verlag, pp 121–127

    Google Scholar 

  59. Gibbs S, Waters WE, George CF (1989) The benefits of prescription information leaflets (1) Br J Clin Pharmacol 27: 723–739. (2) Br J Clin Pharmacol 28: 345–351

    Google Scholar 

  60. Morris L (1989) Global assessment of the patient package insert. In: Bogaert MG, Vander Stichele R, Kaufman JM, Lefebvre R (eds). Patient package insert as a source of written drug information. Elsevier. Amsterdam

    Google Scholar 

  61. Vander Stichele R (1989) Patients package inserts: a review of the literature. In: Bogaert MG, Vander Stichele R, Kaufman JM, Lefebvre R (eds). Patient package insert as a source of written drug information. Elsevier, Amsterdam

    Google Scholar 

  62. Dirks JF, Kinsman RA (1982) Nondichotomous patterns of medication usage: the yes-no fallacy. Clin Pharmacol Ther 31: 413–417

    Google Scholar 

  63. Feinstein AR (1987) Clinimetrics. Yale University Press

  64. Maickel RP (1984) Chemical analysis of marker substances. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 556–567

    Google Scholar 

  65. Silvers A, Russel ML, Insull W (1984) The statistical analysis of adherence data obtained from markers. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 544–555

    Google Scholar 

  66. Levine RJ (1980) Ethical considerations in the development and application of compliance strategies for the treatment of hypertension. In: Haynes RB, Mattson ME, Engebretson TO (eds). Patient compliance to prescribed antihypertensive medication regimens: a report to the National Heart Lung and Blood Institute. (NIH-publication 81-2102) US Government Printing Office

  67. Russel ML (1984) Behavioral aspects of the use of medical markers in clinical trials. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 526–534

    Google Scholar 

  68. Park LC, Lipman RS (1964) A comparison of parental dose deviations reports with pill counts. Psychopharmacologia (1964) 6: 299–302

    Google Scholar 

  69. Wilcox DR, Gillan R, Hare EH (1965) Do psychiatric outpatients take their drugs? Brit Med J 2: 790–792

    Google Scholar 

  70. Porter AMW (1969) Drug defaulting in general practice. Br Med J 1: 218–222

    Google Scholar 

  71. Leirer VO, Morrow DG, Pariante GM, Sheikh JI (1988) Elders' non-adherence, its assessment and computer assisted instruction for medication recall training. J Am Geriatric Soc 36: 877–884

    Google Scholar 

  72. Feinstein AR, Wood HR, Epstein JA, Taranta A, Simpson R, Tursky E (1959) A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. N Eng J Med 260: 697–702

    Google Scholar 

  73. Chaves AD (1960) Results of the PAS Urine test (Phenistix). Am Rev Resp Dis 81: 111–112

    Google Scholar 

  74. Bergman AB, Werner RJ (1963) Failure of children to receive penicillin by mouth. N Engl J Med 268: 1334–1338

    Google Scholar 

  75. Preston DF, Miller FL (1964) The tuberculosis outpatients' defection from therapy. Am J Med Sci 247: 21–25

    Google Scholar 

  76. Gordis L, Marcovitz M, Lilienfeld AM (1969) The inaccuracy in using interviews to estimate patient reliability in taking medications at home. Med Care 7: 49–54

    Google Scholar 

  77. Rickels K, Briscoe E (1970) Assessment of dosage deviation in outpatient drug research. J Clin Pharmacol 10: 152–160

    Google Scholar 

  78. Sheiner L, Rosenberg B, Marathe V, Peck C (1974) Differences in serum digoxin concentrations between out-patients and in-patients: An effect of compliance? Clin Pharmacol Ther 15: 239–246

    Google Scholar 

  79. Gordis L (1979) Conceptual and methodologic problems in measuring patient compliance. In: Haynes RB, Taylor DW, Sackett DL (eds). Compliance in health care. Baltimore: The Johns Hopkins University Press

    Google Scholar 

  80. Roth HP, Caron HS (1978) Accuracy of doctor's estimates and patients' statements on adherence to a drug regimen. Clin Pharmacol Ther 23: 361–370

    Google Scholar 

  81. Norell SE (1981) Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med 15 E: 57–61

    Google Scholar 

  82. Kass MA, Gordon M, Meltzer DW (1986) Can ophthalmologists correctly identify patients defaulting from pilocarpine treatment. Am J Ophthal 101: 515–523

    Google Scholar 

  83. Mattson ME, Friedman LM (1984) Issues in medication adherence assessment in clinical trials of the national Heart, Lung and Blood Institute. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 488–496

    Google Scholar 

  84. Bussey HI, Hawkins DW, Gaspard JJ, Walsh RA (1988) A comparative trial of digoxin and digitoxin in the treatment of congestive heart failure. Pharmacotherapy 8: 235–240

    Google Scholar 

  85. Inui TS, Carter WB, Recoraro RE, Pearlman RA, Dohan JJ (1980) Variations in patient compliance with common long-term drugs. Med Care 18: 986–993

    Google Scholar 

  86. Enlund H, Tuomilehto J, Turakka H (1981) Patient report validated against prescription records for measuring use of and compliance with antihypertensive drugs. Acta Med Scand 209: 271–275

    Google Scholar 

  87. Steiner JF, Koepsell TD, Fihn SD, Inui TS (1988) A general method of compliance assessment using centralized pharmacy records. Med Care 26: 814–823

    Google Scholar 

  88. Roth HP, Caron HS, Hsi BP (1970) Measuring intake of a prescribed medication. A bottle count and a tracer technique compared. Clin Pharmacol Ther 11: 228–237

    Google Scholar 

  89. Mäenpää H, Manninen V, Heinonen OP (1987) Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 8 (Suppl 1): 39–43

    Google Scholar 

  90. Urquhart J (1989) Non-compliance: the ultimate absorption barrier. In: Prescott LF, Nimmo WS (eds). Novel drug delivery and its therapeutic applications. John Wiley & Sons, New York

    Google Scholar 

  91. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, Mitchell WD, Marshall G (1989) The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 46: 169–176

    Google Scholar 

  92. Burris JF, Mroczek WJ (1990) Pill hoarding and hypercompliance [letter]. Clin Pharmacol Ther 47: 547

    Google Scholar 

  93. Young LM, Haakenson CM, Lee KK (1984) Riboflavine use as a drug marker in Veterans Administration Cooperative studies. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 497–504

    Google Scholar 

  94. Roth JK (1980) The pill bottle dessiccant and non-compliance [letter]. JAMA 244: 2263

    Google Scholar 

  95. Thompson WL (1984) Clinical Pharmacology of a marker of patient compulsiveness. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 522–525

    Google Scholar 

  96. Dunbar J (1984) Adherence measures and their utility. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 515–521

    Google Scholar 

  97. Wolen RL, Crabtree RE, Carmichael RH (1984) Tracer microspheres as compliance markers in clinical research. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 540–543

    Google Scholar 

  98. Fales HM (1984) Alternative adherence marker schemes. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 476–578

    Google Scholar 

  99. Rodewald LE, Maiman LA, Faye HR, Borch RF, Forbes GB (1989) Deuterium oxide as a tracer for measurement of compliance in pediatric clinical drug trials. J Pediatr 114: 885–891

    Google Scholar 

  100. Klein PD (1984) Stable isotopic abundances as reflections of ingestion practices. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 568–572

    Google Scholar 

  101. Schwarcz HP (1984) Use of stable isotopes to determine compliance. Proceedings of the workshop on the development of markers or use as adherence measures in clinical studies. Controlled Clin Trials 5 (Suppl 4): 573–587

    Google Scholar 

  102. Geisler A, Andersen E, Vedso S (1968) Depressive patienters medvirken ved medicamentel behandling. Ugerskr Laeg 130: 1803–1806

    Google Scholar 

  103. Caron HS, Roth HP (1968) Patients' cooperation with a medical regimen. Difficulties in identifying the noncooperator. JAMA 203: 922–926

    Google Scholar 

  104. Thompson RH, Stowers JM (1971) The use of a drug marker in a clinical trial. Scot Med J 16: 259–260

    Google Scholar 

  105. Epstein LH, Masek BJ (1978) Behavioral control of medicine compliance. J Appl Behav Anal 11: 1–9

    Google Scholar 

  106. Deutsche KW, Jordahl C, Hobby GL (1960) Clinical usefulness of riboflavin-tagged isoniazid for self-medication in tuberculous patients. Am Rev Resp Dis 82: 1–10

    Google Scholar 

  107. Jones IH (1967) Riboflavine as an indicator of drug taking behaviour. Med J Aust 54: 202–204

    Google Scholar 

  108. Jay S, et al. (1984) Riboflavine, self-report and serum norethindrone. Comparison of their use as indicators of adolescent compliance with oral contraceptives. Am J Dis Child 138: 70–73

    Google Scholar 

  109. Kraus JA (1985) The applicability of riboflavine as a marker for patient compliance. Pharmacol Weekbl 120: 9

    Google Scholar 

  110. Dubbert PM, et al. (1985) Riboflavine as a tracer of medication compliance. J Behav Med 8: 287–299

    Google Scholar 

  111. Babiker IE, Cooke PR, Gillet MG (1989) How useful is riboflavine as a tracer of medication compliance? J Behav Med 12: 25–38

    Google Scholar 

  112. Feely M, Cooke J, Price D, Singleton S, Mehta A, Bradford L, Calvert R (1987) Low-dose phenobarbitone as an indicator of compliance with drug therapy. Br J Clin Pharmacol 24: 77–83

    Google Scholar 

  113. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP (1988) Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily. Clin Pharmacol Ther 44: 540–545

    Google Scholar 

  114. Pullar T, Peaker S, Martin MFR, Bird HA, Feely MP (1988) The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Brit J Rheumatol 27: 381–384

    Google Scholar 

  115. Penn ND, Peaker S, Griffiths AP, Feely M, Tindall H (1988) Use of a pharmacological indicator to monitor compliance with thyroxine. Eur J Clin Pharmacol 35: 327–329

    Google Scholar 

  116. Feely M, Price D, Bodansky HJ, Tindall H (1989) The use of pharmacological indicator to assess compliance with drug therapy in patients with poorly controlled type II diabetes. Br J Clin Pharmacol 27: 101P-102P

    Google Scholar 

  117. Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, Roberts BE, Feely MP (1989) Poor compliance is a mayor factor in unstable outpatient control of anticoagulant therapy. Thrombosis Haemostasis 62: 729–732

    Google Scholar 

  118. Mäenpää H, Javela K, Pikkarainen J, Mälkönen M, Heinonen OP, Maninnen V (1987) Minimal doses of digoxin: A new marker for compliance to medication. Eur Heart J 8 (Suppl 1): 31–37

    Google Scholar 

  119. Mäenpää H, Manninen V, Heinonen OP (1989) Compliance with medication. Internal Medicine for the specialist (sept): 55–64

  120. Moulding T (1962) Proposal for a time-recording pill dispenser as a method for studying and supervising the self-administration of drugs. Am Rev Respir Dis 48: 32–37

    Google Scholar 

  121. Moulding TS (1974) Self-administration of isoniazid and thiacetazone studied by the medication monitor. Chest 65: 234–235

    Google Scholar 

  122. Moulding TS (1979) The unrealized potential of the medication monitor. Clin Pharmacol Ther 25: 131–136

    Google Scholar 

  123. Yee RD, Hahn PM, Christensen RE (1974) Medication monitor for ophthalmology. Am J Ophtal 78: 774–778

    Google Scholar 

  124. Norell SE, Granström PA, Wassèn R (1980) A medication monitor and fluorescein technique designed to study medication behaviour. Acta Ophthal 58: 459–467

    Google Scholar 

  125. Kass MA, Meltzer D, Gordon M, Cooper D, Goldberg J (1986) Compliance with topical pilocarpine treatment. Am J Ophthal 101: 515–523

    Google Scholar 

  126. Kass MA, Gordon M, Morley RE, Meltzer DW, Goldberg JJ (1987) Compliance with topical timoptol treatment. Am J Ophthal 103: 188–193

    Google Scholar 

  127. Eisen SA, Hanpeter JA, Kreuger LW, Gard M (1987) Monitoring medication compliance: description of a new device. J Compliance Health Care 2: 131–142

    Google Scholar 

  128. Cheung R, Sullens CM, Seal D, Dickins J, Nicholson PW, Deshmukh AA, Denham MJ, Dobbs SM (1988) The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community. Br J Clin Pharmacol 26: 391–398

    Google Scholar 

  129. Averbuch M, Weintraub M, Pollock DJ (1988) Compliance monitoring in clinical trials: the MEMS device [abstract]. Clin Pharmacol Ther 43: 185

    Google Scholar 

  130. Rudd P, Marshall G (1987) Resolving problems of measuring compliance with medication monitors. J Compliance Health Care 2: 23–25

    Google Scholar 

  131. First International Symposium on compliance monitoring. Heidelberg, West-Germany. June 6, 1988. Unpublished proceedings. Available from Aprex Corporation, Fremont, California, USA

  132. Averbuch M, Weintraub M, Byrne L, LeHalpere A, Rubio A (1989) Electronic compliance monitoring in a phase I clinical trial [abstract]. Clin Pharmacol Ther 45: 153

    Google Scholar 

  133. Rudd P, Ahmed S (1989) Pill count vs electronic monitor in a drug trial [abstract]. Clin Pharmacol Ther 45: 159

    Google Scholar 

  134. Engström FW, Urquhart J (1989) Electronic monitoring of medication compliance in depressed outpatients [abstract]. Clin Pharmacol Ther 45: 159

    Google Scholar 

  135. Kruse W, Schlierf G, Weber E (1989) Dynamically compliance monitoring — its utility for the interpretation of drug trials [abstract]. Eur J Clin Pharmacol 36 (Suppl): A289

    Google Scholar 

  136. Rudd J, Ahmed S, Zachary V, Barton C (1989) Reinterpreting clinical drug trial results with an electronic monitor. Clin Res 37: 801A

  137. Kruse W, Eggert W, Rampmaier J, Runnebaum B, Weber E (1990) Compliance with shortterm high-dose ethinyl oestradiol in young patients with primary infertility. New insights from the use of electronic devices. Agents Actions [Suppl]: 105–115

  138. Byrne L, Averbuch M, Rubio A, Weintraub M (1990) Compliance (CMPL) measures via medication event monitoring systems (MEMS) as an adjunct in interpreting pharmacokinetic data [abstract]. Clin Pharmacol Ther 47: 152

    Google Scholar 

  139. Kruse W, Schlierf G (1990) Monitoring compliance in clinical trials [letter]. Lancet 335: 803

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heymans Institute of Pharmacology, State University of Gent, Gent, Belgium

    R. Vander Stichele

Authors
  1. R. Vander Stichele
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vander Stichele, R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 41, 27–35 (1991). https://doi.org/10.1007/BF00280102

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00280102

Key words

Search

Navigation